CLINICAL EFFICACY OF LANSOPRAZOLE IN ERADICATION OF HELICOBACTER-PYLORI

A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing an d eradication rates in Helicobacter pylori-associated peptic ulcer dis ease. Seventy-nine patients with gastric ulcers and 54 patients with d uodenal ulcers were randomly assigned to two treatment groups. Group 1 received lansoprazole 30 mg daily for 8 weeks for gastric ulcers or 6 weeks for duodenal ulcers. Group 2 received the group 1 regimen plus amoxicillin 2 g daily for 2 weeks. Healing rates at 8 weeks for the ga stric ulcer patients were 92 and 84% in groups 1 and 2, respectively ( p = not significant), Healing rates at 6 weeks for duodenal ulcers wer e 96% in group 1 and 100% in group 2 (p = not significant), The eradic ation rates of H. pylori for gastric ulcer patients were 21 and 54% in groups 1 and 2, respectively (p < 0.05). The H. pylori eradication ra tes for duodenal ulcer patients were 5 and 73% in groups 1 and 2, resp ectively (p < 0.001). The H. pylori eradication rates in group 2 were significantly higher than in group 1. Lansoprazole was effective for e radicating H. pylori in this study.